With evidence mounting that IDH mutant gliomas constitute a distinct subclass that follows an independent path of tumorigenesis [48], we endeavored to characterize metabolic differences between IDH1 mutant and IDH wildtype gliomas. This evidence concerns the gene IDH2 and central nervous system cancer.